Cited by 1,558SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Spike mutation D614G alters SARS-CoV-2 fitness

Open access

Plante, Jessica A., Liu, Yang, Liu, Jianying, Xia, Hongjie, Johnson, Bryan A., Lokugamage, Kumari G., Zhang, Xianwen, Muruato, Antonio E., Zou, Jing, Fontes-Garfias, Camila R., Mirchandani, Divya, Scharton, Dionna, Bilello, John P., Ku, Zhiqiang, An, Zhiqiang, Kalveram, Birte, Freiberg, Alexander N., Menachery, Vineet D., Xie, Xuping, Plante, Kenneth S., Weaver, Scott C., Shi, Pei-Yong·2021·Nature

DOI 10.1038/s41586-020-2895-3PMC PMC8158177

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein substitution D614G became dominant during the coronavirus disease 2019 (COVID-19) pandemic 1,2. However, the effect of this variant on viral spread and vaccine efficacy remains to be defined. Here we engineered the spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral replication in human lung epithelial cells and primary human airway tissues by increasing the infectivity and stability of virions. Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs, supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission. Sera from hamsters infected with D614 virus exhibit modestly higher neutralization titres against G614 virus than against D614 virus, suggesting that the mutation is unlikely to reduce the ability of vaccines in clinical trials to protect against COVID-19, and that therapeutic antibodies should be tested against the circulating G614 virus. Together with clinical findings, our work underscores the importance of this variant in viral spread and its implications for vaccine efficacy and antibody therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2895-3

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
The New Statistics: Why and How
Cumming, G. (2014) · Psychological Science · doi:10.1177/0956797613504966 · Cited by 3,200
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
HCA Lung Biological Network, Sungnak, W., Huang, N., Bécavin, C., Berg, M., Queen, R., Litvinukova, M., Talavera-López, C., Maatz, H., Reichart, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0868-6 · Cited by 2,501
A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells
Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Self-citation
SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract
Hou, Y. J., Okuda, K., Edwards, C. E., Martinez, D. R., Asakura, T., Dinnon, K. H., Kato, T., Lee, R. E., Yount, B. L., Mascenik, T. M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.042 · Cited by 1,488

Show all 37 references

Research works printed but not linked: 1

Mulligan, M. J. et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586, 589–593 (2020). · DOI · Paper page

Sorted by citations

Items 501–600 of 1,008

Drug repurposing for the treatment of COVID-19
Kato, Y., Nishiyama, K., Nishimura, A., Noda, T., Okabe, K., Kusakabe, T., Kanda, Y., & Nishida, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.04.007 · Cited by 35
Transfer Learning Facilitates the Prediction of Polymer–Surface Adhesion Strength
Shi, J., Albreiki, F., Colón, Y. J., Srivastava, S., & Whitmer, J. K. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01314 · Cited by 27
SARS-CoV-2 serology testing: Progress and challenges
Shi, A. C., & Ren, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113060 · Cited by 28
S glycoprotein diversity of the Omicron variantPreprint
Sarkar, R., Lo, M., Saha, R., Dutta, S., & Chawla‐Sarkar, M. (2021) · medRxiv · doi:10.1101/2021.12.04.21267284 · Cited by 26
Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection
Ratcliff, J., Nguyen, D. V., Fish, M., Rynne, J., Jennings, A., Williams, S. V., Al-Beidh, F., Bonsall, D., Evans, A. L., Golubchik, T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab283 · Cited by 27
Sensitive Detection of SARS-CoV-2 Spike Protein Using an Aptamer Sandwich Assay-Based Electrochemical Biosensor
Kim, H.-M., & Park, J. (2024) · BioChip Journal · doi:10.1007/s13206-024-00174-y · Cited by 28
High Prevalence of SARS-CoV-2 Genetic Variation and D614G Mutation in Pediatric Patients With COVID-19
Pandey, U., Yee, R., Shen, L., Judkins, A. R., Bootwalla, M., Ryutov, A., Maglinte, D. T., Ostrow, D. G., Precit, M. R., Biegel, J. A., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa551 · Cited by 27
Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses
Ghosh, S., & Malik, Y. S. (2020) · Microorganisms · doi:10.3390/microorganisms8111840 · Cited by 28
Molecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic
Komiyama, M. (2021) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20210030 · Cited by 27
The COVID‐19 epidemic in Madagascar: clinical description and laboratory results of the first wave, march‐september 2020
Randremanana, R. V., Andriamandimby, S. F., Rakotondramanga, J. M., Razanajatovo, N. H., Mangahasimbola, R. T., Randriambolamanantsoa, T. H., Ranaivoson, H. C., Rabemananjara, H. A., Razanajatovo, I. M., Razafindratsimandresy, R., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12845 · Cited by 26
COVIDOUTCOME—estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome
Nagy, Á. M., Ligeti, B., Szebeni, J., Pongor, S., & Győrffy, B. (2021) · Database · doi:10.1093/database/baab020 · Cited by 25
Global variation in SARS-CoV-2 proteome and its implication in pre-lockdown emergence and dissemination of 5 dominant SARS-CoV-2 clades
Patro, L. P. P., Sathyaseelan, C., Uttamrao, P. P., & Rathinavelan, T. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104973 · Cited by 27
Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants
Spratt, A. N., Kannan, S. R., Woods, L. T., Weisman, G. A., Quinn, T. P., Lorson, C. L., Sönnerborg, A. B., Byrareddy, S. N., & Singh, K. D. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.06.037 · Cited by 25
M13 Virus Triboelectricity and Energy Harvesting
Kim, H., Lee, J., Lee, J. H., Lee, B. Y., Lee, B. D., Okada, K., Ji, S., Yoon, J., Lee, J. H., & Lee, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01881 · Cited by 26
Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern
Lafon, E., Jäger, M., Bauer, A., Reindl, M., Bellmann‐Weiler, R., Wilflingseder, D., Lass‐Flörl, C., & Posch, W. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.013 · Cited by 27
Conservation and Enhanced Binding of SARS-CoV-2 Omicron Spike Protein to Coreceptor Neuropilin-1 Predicted by Docking Analysis
Baindara, P., Dinata, R., Mandal, S. M., & Schrum, A. G. (2022) · Infectious Disease Reports · doi:10.3390/idr14020029 · Cited by 26
Molecular dynamic simulation suggests stronger interaction of Omicron-spike with ACE2 than wild but weaker than Delta SARS-CoV-2 can be blocked by engineered S1-RBD fraction
Santra, D., & Maiti, S. (2022) · Structural Chemistry · doi:10.1007/s11224-022-02022-x · Cited by 27
Structural evolution of Delta lineage of SARS-CoV-2
Gomari, M. M., Tarighi, P., Choupani, E., Abkhiz, S., Mohamadzadeh, M., Rostami, N., Sadroddiny, E., Baammi, S., Uversky, V. N., & Dokholyan, N. V. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.227 · Cited by 28
Reverse genetics systems for SARS-CoV-2: Development and applications
Cai, H.-L., & Huang, Y. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.10.001 · Cited by 28
Positive selection underlies repeated knockout of ORF8 in SARS-CoV-2 evolution
Wagner, C., Kistler, K. E., Perchetti, G. A., Baker, N., Frisbie, L. A., Torres, L. M., Aragona, F., Yun, C., Figgins, M. D., Greninger, A. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47599-5 · Cited by 30
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variantPreprint
Scheaffer, S. M., Lee, D. W., Whitener, B. M., Ying, B., Wu, K., Jani, H., Martin, P., Amato, N. J., Avena, L. E., Berrueta, D. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.12.507614 · Cited by 26
Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics
Choi, H. M., Moon, S. Y., Yang, H.-I., & Kim, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041737 · Cited by 28
Phylogenomics reveals multiple introductions and early spread of SARS‐CoV‐2 into Peru
Juscamayta‐López, E., Carhuaricra, D., Tarazona, D. D., Valdivia, F., Rojas, N., Lenin Maturrano, H., & Gavilán, R. G. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27167 · Cited by 25
Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines
Yaqinuddin, A., Shafqat, A., Kashir, J., & AlKattan, K. M. (2021) · Vaccines · doi:10.3390/vaccines9080914 · Cited by 25
COVID-19: A review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks
Murugan, C., Ramamoorthy, S., Kuppuswamy, G. P., Murugan, R. K., Sivalingam, Y., & Sundaramurthy, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.10.144 · Cited by 28
Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19
Solomon, M., & Liang, C. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198882 · Cited by 25
Recent progress on rapid diagnosis of COVID-19 by point-of-care testing platforms
Tang, Y., Jiang, D., Wang, X., Liu, Y., & Wei, D. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108688 · Cited by 25
Self-citation
Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: a systematic review
Arabi, M., Al-Najjar, Y. A., Sharma, O., Kamal, I., Javed, A., Gohil, H., Paul, P., Al-Khalifa, A. M., Laws, S., & Zakaria, D. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08328-3 · Cited by 25
The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2
Fang, L., Xu, J., Zhao, Y., Fan, J., Shen, J., Liu, W., & Cao, G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1228128 · Cited by 26
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Dose, Infection, and Disease Outcomes for Coronavirus Disease 2019 (COVID-19): A Review
Brosseau, L. M., Escandón-Vargas, K., Ulrich, A. K., Rasmussen, A. L., Roy, C. J., Bix, G. J., Popescu, S. V., Moore, K. A., & Osterholm, M. T. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab903 · Cited by 27
Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction
Sathi, S. N., Umasankar, P. K., Sreekumar, E., Nair, R. R., Joseph, I., Nori, S. R. C., Philip, J. S., Prasad, R., Navyasree, K. V., Ramesh, S. T., et al. (2022) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00403-4 · Cited by 26
Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27
SARS-CoV-2 variants: A double-edged sword?
Jogalekar, M. P., Veerabathini, A., & Gangadaran, P. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211014146 · Cited by 24
Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia
Díaz, F. J., Aguilar-Jiménez, W., Flórez‐Álvarez, L., Valencia, G., Laiton‐Donato, K., Franco-Muñoz, C., Álvarez-Díaz, D. A., Mercado, M., & Rugeles, M. T. (2020) · Biomédica · doi:10.7705/biomedica.5834 · Cited by 24
Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score
Sen, S. R., Sanders, E. C., Gabriel, K., Miller, B. M., Isoda, H. M., Salcedo, G. S., Garrido, J. E., Dyer, R. P., Nakajima, R., Jain, A., et al. (2021) · mSphere · doi:10.1128/msphere.00203-21 · Cited by 23
COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
Simonetti, M., Zhang, N., Harbers, L., Milia, M. G., Brossa, S., Nguyen, T. T. H., Cerutti, F., Berrino, E., Sapino, A., Bienko, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24078-9 · Cited by 22
SARS-CoV-2: Cross-scale Insights from Ecology and Evolution
Snedden, C. E., Makanani, S. K., Schwartz, S. T., Gamble, A., Blakey, R. V., Borremans, B., Helman, S. K., Espericueta, L., Valencia, A., Endo, A., et al. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.013 · Cited by 21
SARS‐CoV‐2 outbreak in Iran: The dynamics of the epidemic and evidence on two independent introductions
Fattahi, Z., Mohseni, M., Jalalvand, K., Moghaddam, F. A., Ghaziasadi, A., Keshavarzi, F., Yavarian, J., Jafarpour, A., Mortazavi, S. E., Ghodratpour, F., et al. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14104 · Cited by 24
Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2
Zhao, S., Lou, J., Chong, K. C., Cao, L., Zheng, H., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Viruses · doi:10.3390/v13040638 · Cited by 23
There is no “origin” to SARS-CoV-2
Frutos, R., Pliez, O., Gavotte, L., & Devaux, C. A. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112173 · Cited by 27
Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo
Peng, H., Ding, C., Jiang, L., Tang, W., Liu, Y., Zhao, L., Yi, Z., Ren, H., Li, C. V., He, Y., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-2031-7 · Cited by 24
Self-citation
Wastewater surveillance for SARS-CoV-2 in a small coastal community: Effects of tourism on viral presence and variant identification among low prevalence populations
Rainey, A. L., Loeb, J. C., Robinson, S. E., Lednicky, J. A., McPherson, J., Colson, S., Allen, M. J., Coker, E. S., Sabo‐Attwood, T., Maurelli, A. T., et al. (2021) · Environmental Research · doi:10.1016/j.envres.2021.112496 · Cited by 24
Developing an Amplification Refractory Mutation System-Quantitative Reverse Transcription-PCR Assay for Rapid and Sensitive Screening of SARS-CoV-2 Variants of Concern
Xiong, D., Zhang, X., Shi, M., Wang, N., He, P., Dong, Z., Zhong, J., Luo, J., Wang, Y., Yu, J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01438-21 · Cited by 24
Self-citation
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Becker, J., Stanifer, M. L., Leist, S. R., Stolp, B., Maiakovska, O., West, A., Wiedtke, E., Börner, K., Ghanem, A., Ambiel, I., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.024 · Cited by 25
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity
Prüβ, B. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702065 · Cited by 26
Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
SARS-CoV-2 mutations acquired during serial passage in human cell lines are consistent with several of those found in recent natural SARS-CoV-2 variants
Chung, H., Noh, J. Y., Koo, B., Hong, J. J., & Kim, H. K. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.022 · Cited by 25
SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant
Meyerowitz, E. A., & Richterman, A. G. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.007 · Cited by 26
The ORF8 Protein of SARS-CoV-2 Modulates the Spike Protein and Its Implications in Viral Transmission
Chou, J.-M., Tsai, J.-L., Hung, J.-N., Chen, I.-H., Chen, S.-T., & Tsai, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.883597 · Cited by 24
Multifaceted Assessment of Wastewater-Based Epidemiology for SARS-CoV-2 in Selected Urban Communities in Davao City, Philippines: A Pilot Study
Otero, M. C. B., Murao, L. A. E., Limen, M. A. G., Caalim, D. R. A., Gaite, P. L. A., Bacus, M. G., Acaso, J. T., Miguel, R. M., Corazo, K., Knot, I. E., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19148789 · Cited by 28
Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022
Sharif, N., Alzahrani, K. J., Ahmed, S. N., Khan, A., Banjer, H. J., Alzahrani, F. M., Parvez, A. K., & Dey, S. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271074 · Cited by 26
Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection
Li, Q., Vijaykumar, K., Phillips, S. E., Hussain, S. S., Huynh, N. V., Petty, C. F., Lever, J. E. P., Foote, J. B., Ren, J., Campos, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.163962 · Cited by 23
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24
Structure-guided antibody cocktail for prevention and treatment of COVID-19
Su, S.-C., Yang, T., Yu, P., Liang, K.-H., Wy, C., Yang, C.-W., Lin, H.-T., Wang, M.-J. S., Lu, R., Tso, H.-C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009704 · Cited by 24
Dominant clade‐featured SARS‐CoV‐2 co‐occurring mutations reveal plausible epistasis: An in silico based hypothetical model
Alam, A. S. M. R. U., Islam, O. K., Hasan, M. S., Islam, M. R., Mahmud, S., Al‐Emran, H. M., Jahid, I. K., Crandall, K. A., & Hossain, M. A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27416 · Cited by 24
The R203M and D377Y mutations of the nucleocapsid protein promote SARS-CoV-2 infectivity by impairing RIG-I-mediated antiviral signaling
Li, Y., Li, M., Xiao, H., Liao, F., Shen, M., Ge, W.-W., Ou, J., Liu, Y., Chen, L.-M., Zhao, Y., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1012886 · Cited by 16
Self-citation
Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain
Smaoui, M. R., & Yahyaoui, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-88696-5 · Cited by 21
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
Winkler, M. S., Skirecki, T., Brunkhorst, F. M., Cajander, S., Cavaillon, J., Ferrer, R., Flohé, S. B., García‐Salido, A., Giamarellos‐Bourboulis, E. J., Girardis, M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103291 · Cited by 26
Stability of SARS-CoV-2 Spike G614 Variant Surpasses That of the D614 Variant after Cold Storage
Huang, S., Kung, Y.-A., Huang, P.-N., Chang, S.-Y., Gong, Y., Han, Y.-J., Chiang, H.-J., Liu, K., Lee, K.-M., Chang, C.-Y., et al. (2021) · mSphere · doi:10.1128/msphere.00104-21 · Cited by 23
Minipool testing for SARS‐CoV ‐2 RNA in United States blood donors
Bakkour, S., Saá, P., Groves, J. A., Montalvo, L., Germanio, C. D., Best, S. M., Grebe, E., Livezey, K., Linnen, J. M., Strauss, D., et al. (2021) · Transfusion · doi:10.1111/trf.16511 · Cited by 23
Effect of clinical isolate or cleavage site mutations in the SARS-CoV-2 spike protein on protein stability, cleavage, and cell–cell fusion
Barrett, C. T., Neal, H. E., Edmonds, K. L., Moncman, C. L., Thompson, R., Branttie, J. M., Boggs, K. B., Wu, C., Leung, D. W., & Dutch, R. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100902 · Cited by 28
A Novel SARS-CoV-2 Viral Sequence Bioinformatic Pipeline Has Found Genetic Evidence That the Viral 3′ Untranslated Region (UTR) Is Evolving and Generating Increased Viral Diversity
Farkas, C., Mella, A., Turgeon, M., & Haigh, J. J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.665041 · Cited by 26
SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications
Yuan, L., Tang, Q., Zhu, H., Guan, Y., Cheng, T., & Xia, N. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1976598 · Cited by 20
Structure–Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda
Liu, S., Huynh, T., Stauft, C. B., Wang, T. T., & Luan, B. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01058 · Cited by 22
Lineage Divergence and Vector-Specific Adaptation Have Driven Chikungunya Virus onto Multiple Adaptive Landscapes
Chen, R., Plante, J. A., Plante, K. S., Yun, R., Shinde, D., Liu, J., Haller, S., Mukhopadhyay, S., & Weaver, S. C. (2021) · mBio · doi:10.1128/mbio.02738-21 · Cited by 23
Self-citation
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Development of antibody resistance in emerging mutant strains of SARS CoV‐2: Impediment for COVID‐19 vaccines
Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23
Self-citation
Wastewater and marine bioindicators surveillance to anticipate COVID-19 prevalence and to explore SARS-CoV-2 diversity by next generation sequencing: One-year study
Novoa, B., Ríos-Castro, R., Otero‐Muras, I., de Gouveia, S. M. A. F., Cabo, A., Saco, A., Rey-Campos, M., Pájaro, M., Fajar, N. M., Aranguren, R., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155140 · Cited by 23
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25
COVID-19: The Effect of Host Genetic Variations on Host–Virus Interactions
Chakravarty, S. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00637 · Cited by 23
Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies
Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 24
Genomic and epidemiological characteristics of SARS-CoV-2 in Africa
Lamptey, J., Oyelami, F. O., Owusu, M., Nkrumah, B., Idowu, O. P., Adu‐Gyamfi, E. A., Czika, A., El‐Duah, P., Yeboah, R., Sylverken, A. A., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009335 · Cited by 22
Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka
Pattabiraman, C., Prasad, P., George, A. K., Sreenivas, D., Rasheed, R., Reddy, N. V. K., Desai, A. S., & Ravi, V. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16768.1 · Cited by 21
SARS-CoV-2 Infects Hamster Testes
Campos, R. K., Camargos, V. N., Azar, S. R., Haines, C. A., Eyzaguirre, E. J., & Rossi, S. L. (2021) · Microorganisms · doi:10.3390/microorganisms9061318 · Cited by 24
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
Wu, J., Zhang, L., Zhang, Y., Wang, H., Ding, R., Nie, J., Li, Q., Liu, S., Yu, Y., Yang, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687869 · Cited by 23
Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains
Taghizadeh, P., Salehi, S., Heshmati, A., Houshmand, S. M., InanlooRahatloo, K., Mahjoubi, F., Sanati, M. H., Yari, H., Alavi, A., Jamehdar, S. A., et al. (2021) · Virology · doi:10.1016/j.virol.2021.06.004 · Cited by 21
Molecular detection of SARS-CoV-2 being challenged by virus variation and asymptomatic infection
Jiang, C., Li, X., Ge, C., Ding, Y., Zhang, T., Cao, S., Meng, L., & Lu, S. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.03.006 · Cited by 21
Multiplicity of Glycosphingolipid-Enriched Microdomain-Driven Immune Signaling
Yokoyama, N., Hanafusa, K., Hotta, T., Oshima, E., Iwabuchi, K., & Nakayama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179565 · Cited by 22
Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure
Egeren, D. V., Novokhodko, A., Stoddard, M., Tran, U., Zetter, B. R., Rogers, M. S., Joseph‐McCarthy, D., & Chakravarty, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-02148-8 · Cited by 20
Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells
de Souza, G. A. P., Bideau, M. L., Boschi, C., Ferreira, L., Wurtz, N., Devaux, C. A., Colson, P., & Scola, B. L. (2021) · Viruses · doi:10.3390/v14010023 · Cited by 21
Preparation for the challenge of heavily mutated Omicron variant
Song, Y., & Masaki, F. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.679 · Cited by 21
Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India
Singh, P., Sharma, K. K., Singh, P., Bhargava, A., Negi, S. S., Sharma, P., Bhise, M. P., Tripathi, M. K., Jindal, A., & Nagarkar, N. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105404 · Cited by 22
SARS-CoV-2 Variants and Vaccination
Liu, Y., Liu, J., & Shi, P. (2022) · Zoonoses · doi:10.15212/zoonoses-2022-0001 · Cited by 22
Self-citation
Tetra-primer ARMS-PCR combined with dual-color fluorescent lateral flow assay for the discrimination of SARS-CoV-2 and its mutations with a handheld wireless reader
Wang, Y., Chen, H., Wei, H., Rong, Z., & Wang, S. (2022) · Lab on a Chip · doi:10.1039/d1lc01167g · Cited by 22
Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS‐CoV‐2 variants
Wang, Q., Ye, S., Zhou, Z., Li, J., Lv, J., Hu, B., Yuan, S., Qiu, Y., & Ge, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28116 · Cited by 21
A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
Chonira, V., Kwon, Y. D., Gorman, J., Case, J. B., Ku, Z., Simeon, R. L., Casner, R. G., Harris, D. R., Olia, A. S., Stephens, T., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01193-2 · Cited by 23
Self-citation
[Epidemiology of HIV-associated malignancies].
Launay, O., & Guillevin, L. (2003) · PubMed · Cited by 22
N440K variant of SARS-CoV-2 has Higher Infectious FitnessPreprint
Tandel, D., Gupta, D., Sah, V., & Harshan, K. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.30.441434 · Cited by 21
The SARS-CoV-2 Omicron (B.1.1.529) variant exhibits altered pathogenicity, transmissibility, and fitness in the golden Syrian hamster modelPreprint
Yuan, S.-F., Ye, Z.-W., Liang, R., Tang, K., Zhang, A., Lu, G., Ong, C., Poon, V., Chan, C., Mok, B.-B. W., et al. (2022) · bioRxiv · doi:10.1101/2022.01.12.476031 · Cited by 26
Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Ioannou, G. N., O’Hare, A. M., Berry, K., Fan, V. S., Crothers, K. A., Eastment, M. C., Locke, E. R., Green, P. K., Shah, J. A., & Dominitz, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab419 · Cited by 21
COVID‐19: emergence and mutational diversification of SARS‐CoV‐2
Brüssow, H. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13800 · Cited by 23
Respiratory Viral Shedding in Healthcare Workers Reinfected with SARS-CoV-2, Brazil, 2020
Amorim, M. R., de Souza, W. M., Barros, A. C. G., de Toledo-Teixeira, D. A., Bispo-dos-Santos, K., Simeoni, C. L., Parise, P. L., Vieira, A., Forato, J., Claro, I. M., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2706.210558 · Cited by 21
Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed Patients
Deng, X., Evdokimova, M., O’Brien, A., Rowe, C. L., Clark, N. M., Harrington, A., Reid, G., Uprichard, S. L., & Baker, S. C. (2021) · Viruses · doi:10.3390/v13091743 · Cited by 21
Application of omics technology to combat the COVID‐19 pandemic
Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 20
BepiTBR: T-B reciprocity enhances B cell epitope prediction
Zhu, J. J., Gouru, A., Wu, F., Berzofsky, J. A., Xie, Y., & Wang, T. (2022) · iScience · doi:10.1016/j.isci.2022.103764 · Cited by 21
Association between COVID-19 Diagnosis and Coronary Artery Thrombosis: A Narrative Review
Nappi, F., Giacinto, O., Ellouze, O., Nenna, A., Singh, S. S. A., Chello, M., Bouzguenda, A., & Copie, X. (2022) · Biomedicines · doi:10.3390/biomedicines10030702 · Cited by 22
Evolutionary history and introduction of SARS-CoV-2 Alpha VOC/B.1.1.7 in Pakistan through international travelers
Nasir, A., Bukhari, A. R., Trovão, N. S., Thielen, P., Kanji, A., Mahmood, S. F., Ghanchi, N. K., Ansar, Z., Merritt, B. B., Mehoke, T. S., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac020 · Cited by 21
N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry
Wang, D., Zhou, B., Keppel, T. R., Solano, M. I., Baudys, J., Goldstein, J. M., Finn, M. G., Fan, X., Chapman, A. P., Bundy, J. L., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02904-w · Cited by 19
Evidence for selection on SARS-CoV-2 RNA translation revealed by the evolutionary dynamics of mutations in UTRs and CDSs
Zhu, L., Wang, Q., Zhang, W., Hu, H., & Xu, K. (2022) · RNA Biology · doi:10.1080/15476286.2022.2092351 · Cited by 21

Authors: Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., Mirchandani, D., Scharton, D., Bilello, J. P., Ku, Z., An, Z., Kalveram, B., Freiberg, A. N., Menachery, V. D., Xie, X., Plante, K. S., Weaver, S. C., & Shi, P.-Y.
Affiliations: The University of Texas Medical Branch at Galveston (US)
Gilead Sciences (United States) (US)
Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
Corresponding author: Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
ORCID: Plante, Jessica A.
Liu, Jianying
Xia, Hongjie
Johnson, Bryan A.
Zhang, Xianwen
Zou, Jing
Fontes-Garfias, Camila R.
Scharton, Dionna
Bilello, John P.
Ku, Zhiqiang
An, Zhiqiang
Freiberg, Alexander N.
Menachery, Vineet D.
Xie, Xuping
Plante, Kenneth S.
Weaver, Scott C.
Shi, Pei-Yong
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-10-26
Volume: 592
Issue: 7852
Pages: 116-121
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2895-3
PMC: PMC8158177
OpenAlex: W3093768302
Cited by: 1,558
References: 37
Citations by year: 2026: 37 · 2025: 73 · 2024: 120 · 2023: 174 · 2022: 427 · 2021: 670 · 2020: 55
FWCI: 43.60
Type: journal article
Language: en
Update notices: correction (2021-06-15)
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
PubMed Central (submittedVersion, cc-by-nc-nd)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Amon G. Carter Foundation
John S. Dunn Foundation (AI145617)
University of Texas System
Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation (AI134907)
National Institutes of Health (AG049042, TL1TR001440, AI145617, AI142759, UL1TR001439)
National Institute on Aging (AI142759, AG049042, R00AG049092)
National Institute of Allergy and Infectious Diseases (R43AI145617, AI142759, R24AI120942, R01AI134907, R21AI145400, U01AI151801, U19AI142759, R01AI153602, AI153602, AG049042, AI134907, AI145617, UC7AI094660)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: SARS-CoV-2, viral fitness, viral replication, upper respiratory tract infection, virus transmission, neutralizing antibodies, vaccine efficacy, hamster model, lung epithelial cells, therapeutic antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Spike mutation D614G alters SARS-CoV-2 fitness

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks